α-Synuclein molecular behavior and proteomic profiling distinguish subtypes of Lewy body disorders
Objective: We hypothesized that the clinical heterogeneity found in Lewy body disorders is a consequence of the molecular diversity of αSyn between different patients as…Effect of Venglustat by GBA Mutation Severity in Patients With Parkinson’s Disease
Objective: Report outcomes from Part 2 of the phase 2 MOVES-PD trial (NCT02906020) in patients with PD stratified by glucocerebrosidase (GBA) gene mutation severity. Background:…Ultrastructural Characterization of Monocytes in Parkinson’s Disease and GBA mutations
Objective: To identify morphological changes in circulating CD14+ monocytes in manifesting and non-manifesting carriers of mutations of the GBA gene and Parkinson’s disease (PD). Background: Mutations of…Lipid metabolism alterations in the lysosomal membrane promotes chaperone-mediated autophagy dysfunction and alpha-synuclein pathology in Parkinson’s disease associated to GBA
Objective: The objective of this study was to generate and characterize a new in vitro neuronal model of Parkinson's diseases associated to GBA (PD-GBA) that…Close relationship between CSF lipidomic alterations and cognitive decline in Parkinson’s disease.
Objective: To clarify what the lipidome of biological samples reflects in the pathology of Parkinson’s disease (PD). Background: The lipid pattern in the cerebrospinal fluid…PLA2G6-Associated Neurodegeneration: A Continuum of Phenotypes
Objective: To characterize the spectrum of phenotypes of PLA2G6-associated neurodegeneration in a single patient. Background: The phospholipase A2 Group VI (PLA2G6) gene encodes a cytosolic and…Sensitive biomarker of Parkinson’s disease linked to mutations in the glucocerebrosidase gene
Objective: To find a biomarker for development of Parkinson’s disease (PD) in carriers of mutations in the glucocerebrosidase gene (GBA). Background: Mutations in the GBA…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Correlation and comparison of the lipid profile and the body fat mass in people with Parkinson’s disease submitted to three physical therapies
Objective: To correlate and to compare changes on the lipid profile (LP) and on the body fat mass in people with Parkinson's disease (PD) submitted…Post mortem fatty acid abnormalities in the cerebellar cortex of patients with essential tremor
Objective: The objective of the study was to compare fatty acids (FA) profiles within different fractions of phospholipids retrieved from the cerebellum of patients who…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »